• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用血清学数据洞察 SARS-CoV-2 的 RT-PCR 检测实际性能:一项队列研究。

Insight into the practical performance of RT-PCR testing for SARS-CoV-2 using serological data: a cohort study.

机构信息

Department of Public Health Information, Shenzhen Center for Disease Control and Prevention, Shenzhen, China.

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

出版信息

Lancet Microbe. 2021 Feb;2(2):e79-e87. doi: 10.1016/S2666-5247(20)30200-7. Epub 2021 Jan 19.

DOI:10.1016/S2666-5247(20)30200-7
PMID:33495759
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7816573/
Abstract

BACKGROUND

Virological detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) through RT-PCR has limitations for surveillance. Serological tests can be an important complementary approach. We aimed to assess the practical performance of RT-PCR-based surveillance protocols and determine the extent of undetected SARS-CoV-2 infection in Shenzhen, China.

METHODS

We did a cohort study in Shenzhen, China and attempted to recruit by telephone all RT-PCR-negative close contacts (defined as those who lived in the same residence as, or shared a meal, travelled, or socially interacted with, an index case within 2 days before symptom onset) of all RT-PCR-confirmed cases of SARS-CoV-2 detected since January, 2020, via contact tracing. We measured anti-SARS-CoV-2 antibodies in serum samples from RT-PCR-negative close contacts 2-15 weeks after initial virological testing by RT-PCR, using total antibody, IgG, and IgM ELISAs. In addition, we did a serosurvey of volunteers from neighbourhoods with no reported cases, and from neighbourhoods with reported cases. We assessed rates of infection undetected by RT-PCR, performance of RT-PCR over the course of infection, and characteristics of individuals who were seropositive on total antibody ELISA but RT-PCR negative.

FINDINGS

Between April 12 and May 4, 2020, we enrolled and collected serological samples from 2345 (53·0%) of 4422 RT-PCR-negative close contacts of cases of RT-PCR-confirmed SARS-CoV-2. 1175 (50·1%) of 2345 were close contacts of cases diagnosed in Shenzhen with contact tracing details, and of these, 880 (74·9%) had serum samples collected more than 2 weeks after exposure to an index case and were included in our analysis. 40 (4·5%) of 880 RT-PCR-negative close contacts were positive on total antibody ELISA. The seropositivity rate with total antibody ELISA among RT-PCR-negative close contacts, adjusted for assay performance, was 4·1% (95% CI 2·9-5·7), which was significantly higher than among individuals residing in neighbourhoods with no reported cases (0·0% [95% CI 0·0-1·1]). RT-PCR-positive individuals were 8·0 times (95% CI 5·3-12·7) more likely to report symptoms than those who were RT-PCR-negative but seropositive, but both groups had a similar distribution of sex, age, contact frequency, and mode of contact. RT-PCR did not detect 48 (36% [95% CI 28-44]) of 134 infected close contacts, and false-negative rates appeared to be associated with stage of infection.

INTERPRETATION

Even rigorous RT-PCR testing protocols might miss a substantial proportion of SARS-CoV-2 infections, perhaps in part due to difficulties in determining the timing of testing in asymptomatic individuals for optimal sensitivity. RT-PCR-based surveillance and control protocols that include rapid contact tracing, universal RT-PCR testing, and mandatory 2-week quarantine were, nevertheless, able to contain community spread in Shenzhen, China.

FUNDING

The Bill & Melinda Gates Foundation, Special Foundation of Science and Technology Innovation Strategy of Guangdong Province, and Key Project of Shenzhen Science and Technology Innovation Commission.

摘要

背景

通过 RT-PCR 对严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)进行病毒学检测对监测有局限性。血清学检测可能是一种重要的补充方法。我们旨在评估基于 RT-PCR 的监测方案的实际性能,并确定在中国深圳未检测到 SARS-CoV-2 感染的程度。

方法

我们在中国深圳进行了一项队列研究,并试图通过电话招募所有 RT-PCR 阴性的密切接触者(定义为与确诊的 SARS-CoV-2 病例同住一住所、共同用餐、共同旅行或在症状出现前 2 天内共同社交的密切接触者),这些病例是通过接触追踪自 2020 年 1 月以来检测到的。我们使用总抗体、IgG 和 IgM ELISA 在 RT-PCR 初次病毒学检测后 2-15 周,从 RT-PCR 阴性的密切接触者的血清样本中测量抗 SARS-CoV-2 抗体。此外,我们对无报告病例的社区和有报告病例的社区的志愿者进行了血清学调查。我们评估了 RT-PCR 漏检的感染率、RT-PCR 检测过程中的性能以及总抗体 ELISA 呈阳性但 RT-PCR 阴性的个体特征。

结果

2020 年 4 月 12 日至 5 月 4 日期间,我们招募并收集了 4422 名 RT-PCR 确诊 SARS-CoV-2 病例的 2345 名(53.0%)RT-PCR 阴性密切接触者的血清样本。在这 2345 名患者中,有 1175 名(50.1%)是通过接触追踪在深圳确诊的病例的密切接触者,其中 880 名(74.9%)有暴露于指数病例后 2 周以上的血清样本,并纳入我们的分析。880 名 RT-PCR 阴性密切接触者中有 40 名(4.5%)在总抗体 ELISA 上呈阳性。在考虑了检测性能的情况下,RT-PCR 阴性密切接触者的总抗体 ELISA 阳性率为 4.1%(95%CI 2.9-5.7),显著高于无报告病例社区的个体(0.0%[95%CI 0.0-1.1])。RT-PCR 阳性个体报告症状的可能性是 RT-PCR 阴性但血清学阳性个体的 8.0 倍(95%CI 5.3-12.7),但两组的性别、年龄、接触频率和接触模式分布相似。RT-PCR 未能检测到 134 名感染密切接触者中的 48 名(36%[95%CI 28-44]),且假阴性率似乎与感染阶段有关。

解释

即使是严格的 RT-PCR 检测方案也可能会错过相当一部分 SARS-CoV-2 感染,部分原因可能是难以确定无症状个体的检测时间以获得最佳敏感性。然而,包括快速接触追踪、普遍的 RT-PCR 检测和强制性 2 周隔离在内的基于 RT-PCR 的监测和控制方案仍能控制中国深圳的社区传播。

资助

比尔及梅琳达·盖茨基金会、广东省科技计划项目、深圳市科技计划项目。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3411/7871337/f941f650a965/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3411/7871337/0f45bdcf276d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3411/7871337/d5de1e14296b/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3411/7871337/f941f650a965/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3411/7871337/0f45bdcf276d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3411/7871337/d5de1e14296b/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3411/7871337/f941f650a965/gr3.jpg

相似文献

1
Insight into the practical performance of RT-PCR testing for SARS-CoV-2 using serological data: a cohort study.利用血清学数据洞察 SARS-CoV-2 的 RT-PCR 检测实际性能:一项队列研究。
Lancet Microbe. 2021 Feb;2(2):e79-e87. doi: 10.1016/S2666-5247(20)30200-7. Epub 2021 Jan 19.
2
Antibody tests for identification of current and past infection with SARS-CoV-2.用于识别当前和既往感染新型冠状病毒2的抗体检测。
Cochrane Database Syst Rev. 2020 Jun 25;6(6):CD013652. doi: 10.1002/14651858.CD013652.
3
SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study.SARS-CoV-2 血清流行率和高危密切接触者的传播风险因素:一项回顾性队列研究。
Lancet Infect Dis. 2021 Mar;21(3):333-343. doi: 10.1016/S1473-3099(20)30833-1. Epub 2020 Nov 2.
4
Antibody tests for identification of current and past infection with SARS-CoV-2.抗体检测用于鉴定 SARS-CoV-2 的现症感染和既往感染。
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.
5
Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection.用于 SARS-CoV-2 感染诊断的快速、即时抗原和基于分子的检测。
Cochrane Database Syst Rev. 2021 Mar 24;3(3):CD013705. doi: 10.1002/14651858.CD013705.pub2.
6
Association of Age With Likelihood of Developing Symptoms and Critical Disease Among Close Contacts Exposed to Patients With Confirmed SARS-CoV-2 Infection in Italy.意大利接触确诊 SARS-CoV-2 感染患者的密切接触者中,年龄与出现症状和重症疾病的可能性之间的关系。
JAMA Netw Open. 2021 Mar 1;4(3):e211085. doi: 10.1001/jamanetworkopen.2021.1085.
7
Universal screening for SARS-CoV-2 infection: a rapid review.SARS-CoV-2 感染的普遍筛查:快速综述。
Cochrane Database Syst Rev. 2020 Sep 15;9(9):CD013718. doi: 10.1002/14651858.CD013718.
8
SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study.SARS-CoV-2 血清阳性率及健康青年随后的感染风险:一项前瞻性队列研究。
Lancet Respir Med. 2021 Jul;9(7):712-720. doi: 10.1016/S2213-2600(21)00158-2. Epub 2021 Apr 15.
9
SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study.南非印度马杜赖市首次新冠疫情期间的 SARS-CoV-2 感染和死亡率:一项前瞻性、主动监测研究。
Lancet Infect Dis. 2021 Dec;21(12):1665-1676. doi: 10.1016/S1473-3099(21)00393-5. Epub 2021 Aug 13.
10
Laboratory-based molecular test alternatives to RT-PCR for the diagnosis of SARS-CoV-2 infection.基于实验室的分子检测替代 RT-PCR 用于 SARS-CoV-2 感染的诊断。
Cochrane Database Syst Rev. 2024 Oct 14;10(10):CD015618. doi: 10.1002/14651858.CD015618.

引用本文的文献

1
Assessing COVID-19 seroprevalence and vaccine uptake among women of reproductive-age in Zanzibar's archipelago.评估桑给巴尔群岛育龄妇女中的新冠病毒血清流行率和疫苗接种率。
PLOS Glob Public Health. 2025 Jul 7;5(7):e0003831. doi: 10.1371/journal.pgph.0003831. eCollection 2025.
2
Digital microfluidics methods for nucleic acid detection: A mini review.用于核酸检测的数字微流控方法:一篇综述。
Biomicrofluidics. 2024 Mar 5;18(2):021501. doi: 10.1063/5.0180125. eCollection 2024 Mar.
3
Detection of patients with COVID-19 by the emergency medical services in Lombardy through an operator-based interview and machine learning models.

本文引用的文献

1
False-negative results of initial RT-PCR assays for COVID-19: A systematic review.COVID-19 初始 RT-PCR 检测的假阴性结果:系统评价。
PLoS One. 2020 Dec 10;15(12):e0242958. doi: 10.1371/journal.pone.0242958. eCollection 2020.
2
Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients.COVID-19 患者中针对 SARS-CoV-2 刺突蛋白受体结合域的人抗体反应的持久性和衰减。
Sci Immunol. 2020 Oct 8;5(52). doi: 10.1126/sciimmunol.abe0367.
3
Frequency of serological non-responders and false-negative RT-PCR results in SARS-CoV-2 testing: a population-based study.
通过基于操作员的访谈和机器学习模型,由伦巴第的紧急医疗服务机构对 COVID-19 患者进行检测。
Emerg Med J. 2023 Nov 28;40(12):810-820. doi: 10.1136/emermed-2022-212853.
4
Assessing potential insights of an imperfect testing strategy: Parameter estimation and practical identifiability using early COVID-19 data in India.评估不完善检测策略的潜在见解:利用印度早期新冠疫情数据进行参数估计和实际可识别性分析
Commun Nonlinear Sci Numer Simul. 2023 Aug;123:107280. doi: 10.1016/j.cnsns.2023.107280. Epub 2023 Apr 29.
5
Agnostic Sequencing for Detection of Viral Pathogens.基于无信仰者测序的病毒病原体检测。
Clin Microbiol Rev. 2023 Mar 23;36(1):e0011922. doi: 10.1128/cmr.00119-22. Epub 2023 Feb 27.
6
Deciphering Microbiota of Acute Upper Respiratory Infections: A Comparative Analysis of PCR and mNGS Methods for Lower Respiratory Trafficking Potential.解析急性上呼吸道感染的微生物群:下呼吸道传播潜力的 PCR 和 mNGS 方法比较分析。
Adv Respir Med. 2023 Feb 2;91(1):49-65. doi: 10.3390/arm91010006.
7
Screening and confirmation tests for SARS-CoV-2: benefits and drawbacks.新型冠状病毒2019(SARS-CoV-2)的筛查和确认试验:益处与弊端
Beni Suef Univ J Basic Appl Sci. 2023;12(1):6. doi: 10.1186/s43088-023-00342-3. Epub 2023 Jan 11.
8
A Metasynthesis and Meta-analysis of the Impact and Diagnostic Safety of COVID-19 Symptom Agnostic Rapid Testing in Low- and Middle-Income Countries: Protocol for a Systematic Review.低收入和中等收入国家中新冠病毒症状无关快速检测的影响及诊断安全性的综合分析与荟萃分析:一项系统评价方案
JMIR Res Protoc. 2023 Jan 5;12:e41132. doi: 10.2196/41132.
9
Narrative review on century of respiratory pandemics from Spanish flu to COVID-19 and impact of nanotechnology on COVID-19 diagnosis and immune system boosting.从西班牙流感到 COVID-19 的一个世纪呼吸道传染病的叙述性回顾,以及纳米技术对 COVID-19 诊断和免疫系统增强的影响。
Virol J. 2022 Oct 24;19(1):167. doi: 10.1186/s12985-022-01902-2.
10
McS-Net: Multi-class Siamese network for severity of COVID-19 infection classification from lung CT scan slices.McS-Net:用于从肺部CT扫描切片对新冠病毒感染严重程度进行多类别分类的连体网络
Appl Soft Comput. 2022 Dec;131:109683. doi: 10.1016/j.asoc.2022.109683. Epub 2022 Oct 17.
血清学无应答者和 SARS-CoV-2 检测中假阴性 RT-PCR 结果的频率:一项基于人群的研究。
Clin Chem Lab Med. 2020 Aug 31;58(12):2131-2140. doi: 10.1515/cclm-2020-0978.
4
An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment.评估 COVID-19 血清学检测有助于未来的诊断和暴露评估。
Nat Commun. 2020 Jul 6;11(1):3436. doi: 10.1038/s41467-020-17317-y.
5
Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis.血清学检测在 COVID-19 诊断中的准确性:系统评价和荟萃分析。
BMJ. 2020 Jul 1;370:m2516. doi: 10.1136/bmj.m2516.
6
Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward.SARS-CoV-2 血清学检测:关注、机遇与未来方向。
Sci Immunol. 2020 May 19;5(47). doi: 10.1126/sciimmunol.abc6347.
7
Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure.基于时间的暴露后,逆转录聚合酶链反应(RT-PCR)检测 SARS-CoV-2 的假阴性率的变化。
Ann Intern Med. 2020 Aug 18;173(4):262-267. doi: 10.7326/M20-1495. Epub 2020 May 13.
8
Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study.中国深圳 391 例病例及其 1286 名密切接触者的 COVID-19 流行病学和传播:一项回顾性队列研究。
Lancet Infect Dis. 2020 Aug;20(8):911-919. doi: 10.1016/S1473-3099(20)30287-5. Epub 2020 Apr 27.
9
Antibody responses to SARS-CoV-2 in patients with COVID-19.新型冠状病毒肺炎(COVID-19)患者的 SARS-CoV-2 抗体反应。
Nat Med. 2020 Jun;26(6):845-848. doi: 10.1038/s41591-020-0897-1. Epub 2020 Apr 29.
10
Temporal dynamics in viral shedding and transmissibility of COVID-19.新冠病毒脱落和传播的时间动态。
Nat Med. 2020 May;26(5):672-675. doi: 10.1038/s41591-020-0869-5. Epub 2020 Apr 15.